TRANS.00034 Hematopoietic Stem Cell Transplantation for Diabetes Mellitus

This policy addresses hematopoietic stem cell transplantation (HSCT)—autologous or allogeneic, with ablative or non-myeloablative conditioning—for the treatment of diabetes mellitus. HSCT for diabetes of any type is considered investigational and not medically necessary and is not covered; there are no covered indications for DM under this policy.

"Autologous or allogeneic (ablative and non-myeloablative) hematopoietic stem cell transplantation is consideredinvestigational and not medically necessaryas a treatment of diabetes mellitus."

Sign up to see full coverage criteria, indications, and limitations.